MeiraGTx develops genetic medicines and manufactures them at its own sites in the United Kingdom and Ireland. MGTX reports earnings on Thu, Nov 12, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 24 | Goldman Sachs | Initiated | Hold | |
| Aug 14 | RBC Capital | Target raised | Buy | |
| Jul 8 | RBC Capital | Maintained | Buy | |
| Jul 8 | HC Wainwright & Co. | Reiterated | Buy |
Seasonality
How MGTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.
Whale Options Flow
90DNo whale options trades in MGTX in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MGTX is in one of them and how their past MGTX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered MGTX in an article yet. Here's the latest on the wider market.
About MeiraGTx Holdings
MeiraGTx develops genetic medicines for inherited conditions and more common diseases, including conditions affecting the eye, salivary gland and central nervous system. The company makes its own viral vectors, plasmid DNA and quality control testing at manufacturing sites in London, United Kingdom and Shannon, Ireland. It is also developing a platform that uses oral small molecules to control gene expression in the body. Its headquarters are in New York, and it supplies commercial manufacturing to Johnson & Johnson Innovative Medicine.
- Headquarters
- New York, NY